International Serum Registry?

The International Serum Registry is the central coordinating authority for the collection, standardization, and distribution of outcome data on serum therapy treatments worldwide. It was established in 1975 by protocol of the Geneva Sanitary Bureau in response to the rapid proliferation of serum therapy trials across independent laboratories and hospitals, which had begun to generate incompatible data sets and duplicate therapeutic efforts. The Registry operates as a joint body with administrative headquarters in Geneva and regional data centers in Berlin, Tokyo, and São Paulo, each serving distinct pharmaceutical markets and serum production zones.

The Registry's primary function is epidemiological. Each participating institution — whether a hospital, university laboratory, or commercial serum farm — is required to report treatment outcomes in a standardized format: patient age, infection type identified by culture, serum source, serum lot number, dosage, timing of administration relative to symptom onset, and survival status at defined intervals of one week, one month, three months, and one year. This uniform reporting system replaced the diverse record-keeping methods that had made comparative analysis impossible before 1975. The Kaplan-Meier method was adopted as the statistical standard for survival analysis across all participating facilities, allowing real-time assessment of which serum preparations showed superior efficacy against specific bacterial species in different populations.

A secondary function is inventory management. Because serum therapy depends on blood plasma from immunized animals — primarily horses and rabbits, with smaller quantities from goats and donkeys — supply is finite and production leads are long. The Registry maintains a real-time database of serum stocks by type, location, and age, allowing the Geneva Sanitary Bureau to direct supplies toward regions facing documented epidemiological crisis. During the 1981 outbreak of septicaemia in dairy cattle across northern Europe, the Registry coordinated emergency redistribution of antitoxin serum from North American reserves to prevent cascade infection in human populations dependent on dairy handling.

Registry membership is voluntary but carries substantial institutional advantages. Hospitals with Registry accreditation receive preferential allocation of newly validated serum preparations and access to comparative outcome data that allows rapid identification of ineffective treatments; by contrast, unregistered institutions operate in isolation, unable to benchmark their results against others. This de facto incentive structure has driven near-universal participation among teaching hospitals and major medical centers, though rural clinics and isolated practices remain inconsistently represented. Registry data from 1979 indicated that participating institutions achieved approximately 17 percent higher treatment success rates than unregistered facilities, though debate continues whether this reflects actual serum efficacy differences or systematic reporting bias toward positive outcomes in formal settings.

The Registry's statistical archive has become a critical historical resource. The Institute for the History of Bacteriology in Berlin holds complete Registry records from 1975 onward, and the collection has been digitized and opened to researchers since 2001. Analysis of Registry data by Joshua Lederberg and others established that bacterial resistance to serum therapy — defined as high antibody burden with poor clinical response — could emerge within a single patient course, suggesting that the passive transfer mechanism had inherent limitations. These findings, published between 1979 and 1985, shifted the scientific consensus away from serum therapy as a permanent solution toward a more nuanced understanding of it as a temporary immunological intervention most effective in early infection when bacterial load remained low.

Governance of the Registry has been a source of persistent tension between commercial serum producers and public health authorities. Bayer AG and other manufacturers initially resisted the standardized reporting requirements, arguing that detailed lot documentation would expose proprietary production methods to competitors and regulatory bodies. The 1976 Vienna Accord, brokered by the Geneva Sanitary Bureau, established a compromise: manufacturers submit lot-level data under sealed envelope to the Registry's statistical division, which incorporates them into population analyses without disclosing source, allowing comparative efficacy assessment without revealing synthesis routes. This arrangement has remained largely stable, though periodic calls for complete transparency have emerged from patient advocacy groups in Scandinavia and the Netherlands.

By the early twenty-first century, the Registry had accumulated outcome records on over 800,000 serum therapy courses, making it the largest unified dataset on passive immunotherapy in existence. The quality of this archive depends entirely on the reliability of reporting from individual institutions, and audits conducted in 1992 and 2003 revealed systematic underreporting of fatal outcomes and serum therapy failures by approximately 23 percent across European and North American facilities, a bias that inflated apparent efficacy by several percentage points. Corrections for this bias have been applied retrospectively in published analyses, though the original Registry records remain unchanged.

The Registry has spawned a specialized profession of serum epidemiologists — statisticians and laboratory directors trained to interpret Registry data and conduct population studies. The first formal training program opened in 1981 at the Infectious Disease Research Centre in Cambridge, and by 2010 the discipline had produced over 300 doctoral specialists worldwide. These researchers have documented patterns in serum therapy efficacy that would have been invisible without the Registry's aggregated data: the seasonal variation in response to antitoxin preparations (worse in winter months), the age-dependent decline in serum responsiveness (patients over 60 showing 8-12 percent lower recovery rates), and the critical importance of serum administration within 48 hours of bacteraemia confirmation.